Almirall has begun an option agreement with California’s Bioniz, which could see it buy the entire company and its skin cancer and alopecia drug BNZ-1.
US-based Merck & Co has forged an R&D tie-up with Taiho and Astex Pharmaceuticals, focused on developing small molecule drugs targeting the KRAS gene that has become the subject of
Black Diamond Therapeutics has become the first biotech to announce an IPO in 2020, asking investors to fund a clinical trial to test its new approach to tackling cancer.
Boehringer Ingelheim is to manufacture the first biologic drug approved in China using a new regulatory system, designed to strengthen the country’s domestic pharma infrastructure.